Statements (31)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
protease inhibitor |
| gptkbp:approvalYear |
2012
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
gptkb:J05AX14
|
| gptkbp:brand |
Vitekta
part of Genvoya part of Stribild |
| gptkbp:CASNumber |
697761-98-1
|
| gptkbp:combines |
gptkb:cobicistat
emtricitabine tenofovir |
| gptkbp:contraindication |
severe liver impairment
|
| gptkbp:developedBy |
gptkb:Gilead_Sciences
|
| gptkbp:drugClass |
antiretroviral therapy
|
| gptkbp:eliminationHalfLife |
12.9 hours
|
| gptkbp:hasMolecularFormula |
C23H23ClFNO5
|
| https://www.w3.org/2000/01/rdf-schema#label |
elvitegravir
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits HIV integrase
|
| gptkbp:metabolism |
liver (CYP3A, UGT1A1/3)
|
| gptkbp:pregnancyCategory |
B (US)
|
| gptkbp:proteinBinding |
98-99%
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
diarrhea fatigue headache |
| gptkbp:usedFor |
HIV infection
|
| gptkbp:bfsParent |
gptkb:INSTIs
|
| gptkbp:bfsLayer |
5
|